Prostate cancer vaccine - KAEL-GemVax
Alternative Names: ONY-P; ONY-P1; ONY-P2; Onyvax-PLatest Information Update: 24 Oct 2021
Price :
$50 *
At a glance
- Originator Onyvax
- Developer KAEL-GemVax; National Cancer Institute (USA)
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 23 Jun 2015 Phase-II development appears to be ongoing for Prostate cancer
- 18 Nov 2009 A phase II clinical trial that was taking place at the Mayo Clinic in the US in patients with non-metastatic prostate cancer has been suspended
- 01 Sep 2009 VaxOnco acquires all intellectual property rights to this prostate cancer vaccine from Onyvax